Clinical Rheumatology

, Volume 38, Issue 2, pp 397–402 | Cite as

MicroRNA-146a expression and microRNA-146a rs2910164 polymorphism in Behcet’s disease patients

  • W Ibrahim
  • B. R SakrEmail author
  • E Obaya
  • H Ghonem
Original Article


Behcet’s disease is a chronic, multisystem, inflammatory disease of unknown etiology. Oral ulcers, genital ulcers, cutaneous lesions, and ocular and articular involvement are the prominent features of the disease. The aim of the study was to assess expression of microRNA-146a and its gene polymorphism in Egyptian Behcet’s disease (BD) patients and to evaluate their possible relation with clinical manifestations and activity. This is a case-control study, included 47 BD Egyptian patients, recruited from the Rheumatology outpatient clinic, Kasr Alainy Hospital, Cairo University Hospitals, and 50 healthy controls. BD activity was assessed using the BD Current Activity Score. Quantitative expressions of serum microRNA-146a and microRNA-146a rs2910164 SNP genotyping were performed by real-time polymerase chain reaction (RT-PCR). P values < 0.05 were considered statistically significant. Serum microRNA-146a expression was significantly higher in BD patients than in controls (7. 27 ± 4.11, 1.13 ± .37) (P < 0.001). There was a significant association between microRNA-146a expression and eye activity (P = 0.033) and vascular activity (P = 0.041). miRNA-146a rs2910164 genotyping revealed that the frequency of CC genotype was higher in controls (12 vs 8.5%) and the frequency of GG genotype of rs2910164 was higher in the BD patients (59.6 vs 24%) (P = 0.138). MicroRNA-146a expression in Egyptian BD patients is significantly higher than that in controls; there is significant association between microRNA-146a expression and eye and vascular activity of BD. The frequency of CC genotype of rs2910164 was decreased; frequency of GG genotype of rs2910164 was increased in BD patients as compared to controls, suggesting that GG genotype of rs2910164 confers susceptibility to BD while CC genotype has a protective role against BD development.


Behcet’s disease Genotype MicroRNA Single-nuclear polymorphism 



Behcet’s disease


BD Current Activity Score


central nervous system


micro ribonucleic acids


polymerase chain reaction


Compliance with ethical standards



Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y (2011) Behçet disease: evolution of clinical manifestations. Medicine (Baltimore) 90(2):125–132CrossRefGoogle Scholar
  2. 2.
    Keino H, Okada AA (2007) Behçet’s disease: global epidemiology of an Old Silk Road disease. Br J Ophthalmol 91(12):1573–1574CrossRefGoogle Scholar
  3. 3.
    Sakane T, Takeno M, Suzuki N (1999) Behçet’s disease. N Engl J Med 341(17):1284–1291CrossRefGoogle Scholar
  4. 4.
    Gül A, Inanç M, Ocal L, Aral O, Koniçe M (2000) Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis 59(8):622–625CrossRefGoogle Scholar
  5. 5.
    International Study Group for Behçet’s disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335(8697):1078–1080Google Scholar
  6. 6.
    Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Gonçalves O, Valente J (2009) Behçet’s disease—a contemporary review. J Autoimmun 32(3–4):178–188 2CrossRefGoogle Scholar
  7. 7.
    Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54(3):213–220CrossRefGoogle Scholar
  8. 8.
    Yazici H, Akokan G, Yalçin B, Müftüoğlu A (1977) The high prevalence of HLA-B5 in Behçet’s disease. Clin Exp Immunol 30(2):259–261Google Scholar
  9. 9.
    de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A (2009) HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61(10):1287–1296CrossRefGoogle Scholar
  10. 10.
    Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M (1982) Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol 100(9):1455–1458CrossRefGoogle Scholar
  11. 11.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297CrossRefGoogle Scholar
  12. 12.
    Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355CrossRefGoogle Scholar
  13. 13.
    Singh RP et al (2013) The role of miRNA in inflammation and autoimmunity. Autoimmunity Rev 12:1160–1165CrossRefGoogle Scholar
  14. 14.
    Alevizos I, Illei GG (2010) MicroRNAs as biomarkers in rheumatic diseases. Nat Rev Rheumatol 6:391–398CrossRefGoogle Scholar
  15. 15.
    Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA (2012) miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmunity Rev 11:636–641CrossRefGoogle Scholar
  16. 16.
    Singh S, Rai G, Aggarwal A (2014) Association of microRNA-146a and its target gene IRAK1 polymorphism with enthesitis related arthritis category of juvenile idiopathic arthritis. Rheumatology Int 34:1395–1400CrossRefGoogle Scholar
  17. 17.
    Chen HF, Hu TT, Zheng XY, Li MQ, Luo MH, Yao YX, Chen Q, Yu SY (2013) Association between miR-146a rs2910164 polymorphism and autoimmune diseases susceptibility: a meta-analysis. Gene 521:259–264CrossRefGoogle Scholar
  18. 18.
    Ji J, Cha E, Lee W (2014) Association of miR-146a polymorphisms with systemic lupus erythematosus: a meta-analysis. Lupus 23:1023–1030CrossRefGoogle Scholar
  19. 19.
    Zhang W et al (2014) A single-nucleotide polymorphism of miR-146a and psoriasis: an associationand functional study. J Cellular Molecular Med 18:2225–2234CrossRefGoogle Scholar
  20. 20.
    Luo X, Yang W, Ye DQ, Cui H, Zhang Y, Hirankarn N et al (2011) A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus. PLoS Genet 7(6):e1002128CrossRefGoogle Scholar
  21. 21.
    Zhou Q, Hou S, Liang L, Li X, Tan X, Wei L et al (2014) MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet’s disease and Vogt-Koyanagi-Harada syndrome. Ann Rheum Dis 73(1):170–176CrossRefGoogle Scholar
  22. 22.
    Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 38(8):728–733CrossRefGoogle Scholar
  23. 23.
    Chan YH (2003) Biostatistics 102: quantitative data—parametric & non-parametric tests. Singap Med J 44(8):391–396Google Scholar
  24. 24.
    Chan YH (2003) Biostatistics 103: qualitative data—tests of independence. Singapore Med. J 44(10):498–503Google Scholar
  25. 25.
    Oner T, Yenmis G, Tombulturk K, Cam C, Kucuk OS, Yakicier MC, Dizman D, Sultuybek GK (2015) Association of pre-miRNA-499 rs3746444 and pre-miRNA-146a rs2910164 polymorphisms and susceptibility to Behcet’s disease. Genet Test Mol Biomarkers 19(8):424–430CrossRefGoogle Scholar
  26. 26.
    Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A (2008) Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 105(20):7269–7274CrossRefGoogle Scholar
  27. 27.
    Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY et al (2008) A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis 29(11):2126–2131CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Department of Medical biochemistry and Molecular Biology, Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Rheumatology and Rehabilitation Department, Kasr Al-Ainy HospitalCairo UniversityCairoEgypt

Personalised recommendations